Filing Analysis
BioCardia announced the allowance of a Japanese patent for its Heart3D™ Fusion Imaging software. The patent covers technology used for treatment planning and real-time navigation during the company's CardiAMP Cell Therapy procedures.
Key Facts
- Allowance of Japanese Patent titled 'Target Site Selection, Entry, and Update with Automatic Remote Image Annotation' on April 28, 2026
- The patent protects Heart3D™ Fusion Imaging (Heart3D) software
- The technology is intended for treatment planning and real-time navigation during CardiAMP Cell Therapy procedures
- The disclosure was made under Item 8.01 (Other Events) and included a press release as Exhibit 99.1
BioCardia announced a positive outcome from its formal clinical consultation with Japan's PMDA, which indicated that existing US clinical data for the CardiAMP Cell Therapy is likely sufficient for market clearance in Japan. The company achieved alignment on the use of foreign data, indications for use, and post-marketing study requirements.
Key Facts
- Formal consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) occurred on April 20, 2026.
- PMDA determined that US clinical safety and efficacy evidence for CardiAMP is likely sufficient for Japanese market clearance.
- Alignment was reached on the acceptability of foreign clinical data and the approach for therapy introduction in Japan.
- The company is awaiting official minutes from the PMDA to provide a detailed feedback and filing timeline.
BioCardia, Inc. received a deficiency notice from Nasdaq on April 10, 2026, for failing to maintain the minimum stockholders' equity requirement of $2.5 million. The company's reported equity was $895,000 as of December 31, 2025, significantly below the threshold.
Red Flags
- Stockholders' equity is approximately 64% below the required minimum threshold.
- The deficiency indicates substantial capital depletion as of the end of fiscal year 2025.
- Risk of delisting if the compliance plan is rejected or if the company fails to raise sufficient capital.
Key Facts
- Received Nasdaq notice on April 10, 2026, regarding non-compliance with Listing Rule 5550(b)(1).
- Stockholders' equity was $895,000 as of December 31, 2025, versus the $2.5 million requirement.
- The company has until May 25, 2026, to submit a plan to regain compliance.
- If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the notice date.
- The notice does not result in immediate delisting; the stock continues to trade under 'BCDA'.
BioCardia announced the submission of CardiAMP HF clinical study data to the FDA and plans to discuss an accelerated approval pathway for its heart failure treatment system.
Key Facts
- Submitted CardiAMP HF clinical study data to the FDA on April 2, 2026.
- Seeking accelerated approval pathway for the CardiAMP System for ischemic chronic heart failure with reduced ejection fraction (HFrEF).
- Plans to meet with the FDA to discuss the regulatory pathway for the device.
- The information was disclosed under Item 7.01 (Regulation FD) via a press release.
BioCardia, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 24, 2026.
Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
- The filing was signed by CEO Peter Altman, Ph.D.
BioCardia, Inc. announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter. The device is intended for the delivery of therapeutic and diagnostic agents directly into the heart muscle.
Key Facts
- The FDA accepted the pre-submission package on March 17, 2026.
- The product involved is the Helix Transendocardial Delivery Catheter ('Helix').
- The device is designed for intramyocardial therapeutic and diagnostic agent delivery.
- The filing was made under Item 8.01 (Other Events).
BioCardia announced late-breaking echocardiography results from its Phase III CardiAMP HF clinical trial for ischemic heart failure. The data was presented at the Technology and Heart Failure Therapeutics conference on March 3, 2026.
Key Facts
- The company reported Phase III clinical trial results for ischemic heart failure of reduced ejection fraction (HFrEF).
- Results were presented by Dr. Amish Raval, National Co-Principal Investigator, at the Technology and Heart Failure Therapeutics conference.
- The disclosure was made under Item 7.01 (Regulation FD) and included a press release as Exhibit 99.1.
- The presentation occurred on March 3, 2026.